AllianceBernstein
MRSN

AllianceBernstein’s Mersana Therapeutics MRSN Stock Holding History

AllianceBernstein’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-7,442
Closed -$64K – 3292
2025
Q1 		$64K Hold
7,442
– – ﹤0.01% 3109
2024
Q4 		$266K Hold
7,442
– – ﹤0.01% 2933
2024
Q3 		$352K Hold
7,442
– – ﹤0.01% 2836
2024
Q2 		$374K Buy
7,442
+690
+10% +$49.9K ﹤0.01% 2828
2024
Q1 		$756K Buy
6,752
+2,025
+43% +$201K ﹤0.01% 2404
2023
Q4 		$274K Sell
4,727
-503
-10% -$20.2K ﹤0.01% 2879
2023
Q3 		$166K Sell
5,230
-3,439
-40% -$163K ﹤0.01% 2998
2023
Q2 		$713K Buy
8,669
+4,681
+117% +$685K ﹤0.01% 2465
2023
Q1 		$410K Hold
3,988
– – ﹤0.01% 2651
2022
Q4 		$584K Hold
3,988
– – ﹤0.01% 2545
2022
Q3 		$674K Buy
3,988
+392
+11% +$63.7K ﹤0.01% 2500
2022
Q2 		$415K Buy
3,596
+504
+16% +$47.4K ﹤0.01% 2755
2022
Q1 		$308K Buy
3,092
+8
+0.3% +$935 ﹤0.01% 2862
2021
Q4 		$480K Buy
3,084
+204
+7% +$39.7K ﹤0.01% 2763
2021
Q3 		$679K Hold
2,880
– – ﹤0.01% 2641
2021
Q2 		$978K Hold
2,880
– – ﹤0.01% 2543
2021
Q1 		$1.17M Sell
2,880
-252
-8% -$122K ﹤0.01% 2344
2020
Q4 		$2.08M Hold
3,132
– – ﹤0.01% 1955
2020
Q3 		$1.46M Buy
3,132
+40
+1% +$20.2K ﹤0.01% 2014
2020
Q2 		$1.81M Buy
3,092
+1,532
+98% +$523K ﹤0.01% 1899
2020
Q1 		$227K Buy
1,560
+1,036
+198% +$181K ﹤0.01% 2746
2019
Q4 		$75K Hold
524
– – ﹤0.01% 3068
2019
Q3 		$21K Hold
524
– – ﹤0.01% 3148
2019
Q2 		$53K Buy
+524
New +$61.7K ﹤0.01% 3126
2018
Q3 		– Sell
-2,316
Closed -$1.03M – 3157
2018
Q2 		$1.03M Buy
+2,316
New +$1.02M ﹤0.01% 2303

Other funds holding MRSN

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

AllianceBernstein's MRSN Position: Q2 2025 in Review

AllianceBernstein sold out of Mersana Therapeutics (MRSN) in Q2 2025, closing a stake of 7,442 shares — an estimated $64K sold.

AllianceBernstein first reported a position in MRSN in Q2 2018 and held it in 25 quarters. The position peaked at $2.08M in Q4 2020. 83 funds tracked by Wall St. Rank hold MRSN as of Q2 2025.

  • AllianceBernstein reported no remaining Mersana Therapeutics position as of Q2 2025 after selling out during the quarter.
  • AllianceBernstein sold 7,442 Mersana Therapeutics shares in Q2 2025, an estimated $64K.
  • AllianceBernstein first reported a position in Mersana Therapeutics in Q2 2018 and held it in 25 quarters.
  • AllianceBernstein's Mersana Therapeutics position peaked at $2.08M in Q4 2020.
  • 83 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q2 2025.

Based on AllianceBernstein's 13F filing for Q2 2025, filed 14 Aug 2025.